Track topics on Twitter Track topics that are important to you
EdiGene, a Beijing-Cambridge, MA company that uses gene editing technology to develop novel therapeutics, completed a $10 Million Series pre-B Plus financing. The latest round was led by new investor ...
New round of funding allows EdiGene to hire a clinical development executive from Parexel, Teijin Pharma appoints a president, while...
IPO market is expected to pick up in 2019 after a slow start, due in part to the government shutdown...
The move follows a similar price cut for Amgen's competing PCSK9 inhibitor Repatha and comes as PBMs, including UnitedHealth Group's...
Two weeks after the product's approval, Mylan finally has launched Wixela and revealed a big price cut for the asthma...
EdiGene Inc is founded in 2015, and now headquartered in Beijing, with operational subsidiaries in Guangzhou, China and Cambridge, USA.
We have published hundreds of EdiGene Inc. news stories on BioPortfolio along with dozens of EdiGene Inc. Clinical Trials and PubMed Articles about EdiGene Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of EdiGene Inc. Companies in our database. You can also find out about relevant EdiGene Inc. Drugs and Medications on this site too.